BioRestorative Therapies (BRTX) Q1 2025 earnings summary

Executive summary

• Achieved key clinical milestones in disc/spine and metabolic programs, including FDA Fast Track and expanded IND clearance for BRTX-100.

• Maintained a strong financial position with $9.1 million in cash, cash equivalents, and marketable securities, and no debt at quarter-end.

• Net loss of $5.3 million for Q1 2025, compared to $2.2 million in Q1 2024, driven by higher R&D expenses and increased warrant liability losses.

• Company continues to focus on BRTX-100 (Disc/Spine), ThermoStem (metabolic disorders), and a new cosmetic biologics business.

• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing losses and negative cash flows.

Financial highlights

• Q1 2025 revenue was $25,000, down from $35,000 in Q1 2024; deferred revenue rose to $150,000 from $0.

• Net loss for Q1 2025 was $5,339,799 ($0.64/share), compared to $2,223,255 ($0.33/share) in Q1 2024.

• Loss from operations increased to $4.8 million from $4.1 million year-over-year, mainly due to a 62% rise in R&D costs.

• Cash and cash equivalents at March 31, 2025: $1.23 million; investments in marketable securities: $7.88 million.

• Working capital at quarter-end: $5.2 million, down from $7.4 million at year-end 2024.

Outlook and guidance

• Optimism for continued positive trends in BRTX-100 phase II trial data and further clinical progress.

• Plans to present additional data with a larger patient population soon.

• Ongoing discussions with FDA regarding trial endpoints and potential interim analysis.

• Current funds are insufficient to complete development activities or reach profitability; additional financing will be required.

• If unable to secure timely financing, the company may need to curtail operations or consider liquidation.